Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response accurately and comprehensively reflects the FDA boxed warning on all-cause mortality, including the pooled adjusted risk difference, statement that the cause is not established, and the reserve-for-alternatives language, with consistent support from 1.4, 5.1, and 5.2.
Category Scores
Accurate Statements
WARNING: ALL-CAUSE MORTALITY (boxed warning / increased all-cause mortality with TYGACIL vs comparator; cause not established; reserved for situations when alternative treatments are not suitable).
BOX; 5.1; 1.4 (limitations of use reserve language tied to mortality/efficacy concerns); 5.2 (mortality imbalance context in HAP/VAP trial).
Unsupported Statements
Contradictions
Important Omissions
The specific numeric pooled adjusted risk difference (0.6% with 95% CI 0.1, 1.2) and the death rate percentages (4.0% vs 3.0%) were not explicitly included in the AI claim, though they are present in the label sections provided.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response stays within label wording/meaning for the boxed warning and does not introduce dosing, contraindications, or additional safety claims beyond what is supplied.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Numeric pooled mortality figures present in the boxed warning were not explicitly stated in the AI claim.
Suggested Improvement
Include the boxed warning’s numeric adjusted risk difference (0.6% with 95% CI 0.1, 1.2) as stated in the label text to fully mirror the boxed warning content.